Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Gynaecol Oncol ; 34(5): 446-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24475580

RESUMO

OBJECTIVE: The objectives of this research were to evaluate cases of adenocarcinoma in situ (AIS) and early invasive adenocarcinoma (AC) of the uterine cervix in order to: (1) calculate the pathologic discordance between initial biopsies and final surgical excision specimens and (2) describe the clinical and pathologic factors associated with discordance. MATERIALS AND METHODS: The University of California, Irvine and Long Beach Memorial tumor registries were used to identify 105 women with AIS and early AC treated between 1990 and 2008. The primary endpoint measured was change in diagnosis when comparing pathology from the initial biopsy to specimens from a large loop excision of the transformation zone (LLETZ), cold knife cone (CKC), or hysterectomy. The variables studied were: age, endocervical curettage (ECC), co-existing cervical intraepithelial neoplasia (CIN), race, and insurance type, as surrogates for socioeconomic status. RESULTS: Initial biopsies were diagnosed as AIS and AC in 44% and 56% of patients, respectively. Of the patients with a biopsy diagnosis ofAIS, 29% had a final diagnosis of AC after excisional procedure, and this discordance was not associated with any of the factors studied. CONCLUSIONS: A concerning high rate of discordance between colposcopic-guided punch biopsy and final pathology reinforces the current guidelines to always perform an excisional biopsy following diagnosis of AIS on punch biopsy.


Assuntos
Adenocarcinoma/patologia , Carcinoma in Situ/patologia , Erros de Diagnóstico , Neoplasias do Colo do Útero/patologia , Adenocarcinoma/diagnóstico , Adulto , Carcinoma in Situ/diagnóstico , Feminino , Humanos , Estadiamento de Neoplasias , Neoplasias do Colo do Útero/diagnóstico
2.
Hypertension ; 19(6 Pt 1): 499-507, 1992 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1534312

RESUMO

A multicenter, randomized double-blind study of 6 months' duration was performed in 540 patients (average age 54 years, 57% male) with mild-to-moderate essential hypertension to determine the relative effects on quality of life of cilazapril, atenolol, and nifedipine retard. Quality of life was assessed by using both a self-administered and an interviewer-administered questionnaire; the assessment included a complaint score (symptoms checklist), Health Status Index, assessment of work satisfaction, Psychological General Well-being Index, Profile of Mood States subscales, and life satisfaction assessment. Psychomotor function was measured by the Reitan Trail Making test B. At the end of the trial, diastolic blood pressure had fallen by an average of 15 mm Hg in all three groups, but significantly (p = 0.01) more patients taking cilazapril required the addition of a diuretic (36%) compared with those taking atenolol (25%) or nifedipine retard (24%). No significant differences in quality of life were observed between cilazapril and atenolol during the trial. Symptomatic complaints increased on nifedipine retard (p = 0.02) and contributed to a higher discontinuation rate (21% discontinued treatment compared with 13% and 14% taking atenolol and cilazapril, respectively, p = 0.04). However, a possible improvement in the fatigue subscale (p = 0.04) was also observed on nifedipine retard. The 95% confidence intervals showed that none of the drugs in this trial produced an effect equivalent to that previously reported between captopril and methyldopa in the Psychological General Well Being Index or between captopril and methyldopa or propranolol in Trail Making test B.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Anti-Hipertensivos/uso terapêutico , Atenolol/uso terapêutico , Nifedipino/uso terapêutico , Piridazinas/uso terapêutico , Qualidade de Vida , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Anti-Hipertensivos/efeitos adversos , Atenolol/efeitos adversos , Pressão Sanguínea/efeitos dos fármacos , Cilazapril , Feminino , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Nifedipino/efeitos adversos , Pacientes Desistentes do Tratamento , Piridazinas/efeitos adversos
3.
Dis Aquat Organ ; 34(3): 223-9, 1998 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-9925428

RESUMO

Nucleic acid-based assays have shown promise for diagnosing Renibacterium salmoninarum in tissues and body fluids of salmonids. Development of a nested polymerase chain reaction (PCR) method to detect a 320 bp DNA segment of the gene encoding the p57 protein of R. salmoninarum is described. Whereas a conventional PCR for a 383 bp segment of the p57 gene reliably detected 1000 R. salmoninarum cells per reaction in kidney tissue, the nested PCR detected as few as 10 R. salmoninarum per reaction in kidney tissue. Two DNA extraction methods for the nested PCR were compared and the correlation between replicate samples was generally higher in samples extracted by the QIAamp system compared with those extracted by the phenol/chloroform method. The specificity of the nested PCR was confirmed by testing DNA extracts of common bacterial fish pathogens and a panel of bacterial species reported to cause false-positive reactions in the enzyme-linked immunosorbent assay (ELISA) and the fluorescent antibody test (FAT) for R. salmoninarum. Kidney samples from 74 naturally infected chinook salmon were examined by the nested PCR, the ELISA, and the FAT, and the detected prevalences of R. salmoninarum were 61, 47, and 43%, respectively.


Assuntos
Doenças dos Peixes/microbiologia , Bactérias Gram-Positivas/isolamento & purificação , Infecções por Bactérias Gram-Positivas/veterinária , Rim/microbiologia , Oncorhynchus kisutch/microbiologia , Salmão/microbiologia , Animais , Proteínas de Bactérias/genética , DNA Bacteriano/análise , Ensaio de Imunoadsorção Enzimática/veterinária , Feminino , Técnica Direta de Fluorescência para Anticorpo/veterinária , Genes Bacterianos , Bactérias Gram-Positivas/genética , Infecções por Bactérias Gram-Positivas/microbiologia , Masculino , Reação em Cadeia da Polimerase/veterinária , Sensibilidade e Especificidade
4.
Int J Gynecol Cancer ; 16(3): 1465-9, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16803551

RESUMO

Malignant eccrine spiradenoma is a rare skin tumor of sweat gland origin. We present the first reported case of this tumor in the female genitalia. Due to the rarity of this tumor, there has yet to be an established standard of care. The present case is that of a 41-year-old woman with malignant eccrine spiradenoma of the periclitoral region. She had an 18-month history of a recurrent, painful mass adjacent to the clitoris. Her diagnosis was made after excision of the cystic tumor. The patient then underwent a partial radical vulvectomy with bilateral sentinel lymph node sampling. As malignant eccrine spiradenoma is a rare tumor, no standard care exists for treatment and postoperative management. Based on our review of the literature, wide local excision appears to be the preferred initial treatment. Furthermore, adjuvant chemotherapy and/or radiation does not seem to improve survival in patients with advanced or recurrent cancer. Although lymph node sampling and/or lymphadenectomy is frequently reported in the treatment of this tumor, hematogenous metastasis can also occur. Therefore, these patients require close postoperative follow-up for recurrent disease.


Assuntos
Acrospiroma/diagnóstico , Neoplasias das Glândulas Sudoríparas/diagnóstico , Neoplasias Vulvares/diagnóstico , Adenoma de Glândula Sudorípara/diagnóstico , Adulto , Feminino , Humanos , Recidiva Local de Neoplasia/prevenção & controle , Biópsia de Linfonodo Sentinela/métodos , Neoplasias Vulvares/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA